- New patent, when issued, will be valid until December 2041-- Additional IP complements U.S. market exclusivity awarded to BioLineRx upon FDA approval of APHEXDA® (motixafortide) in September 2023 as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results